Colorectal Cancer: Page 5

NuProbe announces new DNA microsatellite instability assay
By LabPulse.com staff writers
The condition is present in about 15% of colorectal cancer patients and 30% of endometrial cancer patients, and is associated with better immunotherapy response and survival rates, according to the firm. But identifying MSI can be difficult using quantitative polymerase chain reaction (qPCR) testing, the company said. Its assay consists of a thermodynamic model of DNA microsatellite binding that boosts the effectiveness of qPCR testing.
July 25, 2021
2019 04 19 17 18 7022 Dna Strand 400
Natera and BGI launch new assay in China
By LabPulse.com staff writers
The Signatera assay was tested in studies in nonsmall cell lung, bladder, breast, and colorectal cancers and identifies MRD up to two years earlier than standard imaging, the companies said in a release.
June 23, 2021
2019 08 12 20 23 3708 Lab Blood Centrifuge 400
Freenome touts ASCO study of blood test for colorectal adenomas
By LabPulse.com staff writers
The company said that results from the artificial intelligence (AI)-Emerge study will show that the company's multiomics blood test can detect colorectal advanced adenomas with 41% sensitivity and 90% specificity. Freenome said these figures are comparable to existing noninvasive tests for colorectal cancer screening.
January 11, 2021
2019 01 03 22 54 0132 Lab Blood Test1 400
Solvd Health to start colorectal cancer test study
By LabPulse.com staff writers
The Prevent study will be conducted in partnership with Metabiomics, which is a Solvd Health subsidiary, it said. It will enroll up to 12,000 participants at average risk of colorectal cancer between the ages of 45 and 84.
January 7, 2021
2019 11 04 19 56 0311 Colorectal Cancer 400
Bayer, Tempus join forces on cancer testing
By LabPulse.com staff writers
The assay will be available for a subset of patients with metastatic colorectal cancer (mCRC), as well as those with radioactive iodine refractory differentiated metastatic thyroid carcinoma (RAIR thyroid cancers).
December 10, 2020
2019 05 22 19 44 5254 Dna Red Laser 400
Natera wins Medicare coverage for colorectal cancer test
By LabPulse.com staff writers
The LCD will be effective beginning on October 18, 2020, and applies to Medicare beneficiaries with current or prior stage II or stage III colorectal cancer. The future-effective coverage is consistent with Medicare's draft released in August 2019, the company noted.
September 2, 2020
2019 11 04 19 56 0311 Colorectal Cancer 400
Epigenomics touts colon blood test study
By LabPulse.com staff writers
The authors analyzed clinical effectiveness and performance of alternative colorectal cancer screening tests, including methylated septin 9 (mSEPT9), marketed by Epigenomics as Epi proColon. They used five different scenarios, including ones that adjusted for starting age and adherence.
August 12, 2020
2020 04 29 22 14 7161 Lab Blood Dropper V2 400
Mailing FIT kits to Medicaid patients could boost colon cancer screening rates
By Emily Hayes
Using results from a randomized trial, the study simulated the costs and benefits associated with mailed FITs with prepaid return envelopes compared with a mailed reminder alone for colon cancer testing in a population of 35,000 Medicaid patients overdue for screening. Looking over a year, researchers concluded that the anticipated number of colorectal cancer (CRC) screenings, including FIT and colonoscopies, would be higher for the group that had the fecal tests mailed directly (23.2%) than those just getting mailed a reminder about the need for screening (15.8%).
July 20, 2020
2020 07 20 23 57 2002 Colon Polyps 400
Promega microsatellite instability test gets CE Mark
By LabPulse.com staff writers
The polymerase chain reaction-based test is designed to assess MSI status, an increasingly important biomarker in recent years in solid tumors, including colorectal cancer and endometrial cancer. Readings are complementary to standard mismatch repair immunohistochemistry panels and can be used as an independent biomarker to help predict response to immunotherapies, Promega noted in a statement. The company also intends to get the product cleared in the U.S. and China.
June 8, 2020
2019 05 02 23 38 2538 Check Mark 400
VolitionRx highlights liquid biopsy data at ASCO
By LabPulse.com staff writers
In one abstract, researchers describe the results of a pilot study of Volition's sample-enrichment tool for separating short and long nucleosomes in colorectal cancer samples.
May 14, 2020
2017 09 14 23 05 1167 Cancer Cell 400
Caris to highlight precision medicine at ASCO 2020
By LabPulse.com staff writers
The research to be presented includes results from studies of multiple cancer types, such as colorectal, pancreatic, lung, and breast cancer, according to the firm.
May 11, 2020
2017 09 14 23 05 1167 Cancer Cell 400
Bayer, NeoGenomics offer free genomic testing for thyroid, colorectal cancers
By LabPulse.com staff writers
Under the program, genomic cancer testing for NTRK gene fusions will be available at no cost for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). More commonly found in these patients, NTRK fusions have been shown to drive tumor growth and may play a role in disease management, according to the companies.
May 5, 2020
2019 04 22 23 41 4967 Cancer Cell Target2 400
Previous Page
Page 5 of 6
Next Page